BDX:NYE-Becton Dickinson and Company

EQUITY | Medical Instruments & Equipment | New York Stock Exchange

Last Closing

USD 245.42

Change

+2.27 (+0.93)%

Market Cap

USD 35.71B

Volume

1.11M

Analyst Target

USD 270.05
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Becton Dickinson & Co is a medical technology company, engaged in the manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, general public and clinical laboratories.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-21 )

Largest Industry Peers for Medical Instruments & Equipment

ETFs Containing BDX

UMDV:SW iShares US Medical Device.. 5.98 % 0.00 %

-0.05 (-0.53%)

USD 0.18B
IHI iShares U.S. Medical Devi.. 4.74 % 0.43 %

-0.78 (-0.53%)

USD 5.55B
EQTY Kovitz Core Equity ETF 4.15 % 0.00 %

-0.06 (-0.53%)

USD 1.04B
SPQB:XETRA Global X S&P 500® Quarte.. 3.93 % 0.00 %

-0.09 (-0.53%)

USD 0.08B
IBDK 0.00 % 0.10 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
YLDE ClearBridge Dividend Stra.. 0.00 % 0.59 %

-0.05 (-0.53%)

USD 0.04B
VSL 0.00 % 0.65 %

N/A

N/A
LS:CA Middlefield Healthcare & .. 0.00 % 2.21 %

N/A

CAD 0.08B
EWRD:XETRA 0.00 % 0.00 %

N/A

N/A
NSGE:CA NBI Sustainable Global Eq.. 0.00 % 0.00 %

-0.61 (-0.53%)

CAD 0.53B
TULV:CA TD Q U.S. Low Volatility .. 0.00 % 0.00 %

N/A

CAD 0.06B
TACE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Equipment) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.92% 43% F 40% F
Dividend Return 0.34% 90% A- 18% F
Total Return 9.26% 50% F 39% F
Trailing 12 Months  
Capital Gain 12.32% 38% F 85% B
Dividend Return 1.39% 70% C- 24% F
Total Return 13.71% 38% F 83% B
Trailing 5 Years  
Capital Gain 114.21% 30% F 93% A
Dividend Return 11.86% 67% D+ 41% F
Total Return 126.07% 40% F 93% A
Average Annual (5 Year Horizon)  
Capital Gain 17.87% 46% F 91% A-
Dividend Return 19.59% 46% F 90% A-
Total Return 1.72% 64% D 35% F
Risk Return Profile  
Volatility (Standard Deviation) 8.94% 92% A 71% C-
Risk Adjusted Return 219.17% 100% F 99% N/A
Market Capitalization 35.71B 100% F 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Equipment) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.20 31% 6%
Price/Book Ratio 3.15 92% 23%
Price / Cash Flow Ratio 5.72 62% 18%
Price/Free Cash Flow Ratio 35.99 54% 13%
Management Effectiveness  
Return on Equity 4.93% 38% 39%
Return on Invested Capital 6.40% 23% 38%
Return on Assets 1.94% 23% 46%
Debt to Equity Ratio 103.00% 17% 37%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector